 |
|
recombinant MAGE-A3 antigen-specific cancer immunotherapeutic GSK1203486A
A cancer vaccine consisting of a recombinant form of human melanoma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with potential immunostimulatory and antineoplastic activities. Upon administration, recombinant MAGE-A3 antigen-specific cancer immunotherapeutic GSK1203486A may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the MAGE-A3 antigen, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen (TAA) originally discovered in melanoma cells, is expressed by various tumor types. The proprietary immunostimulating adjuvant in this agent is composed of a specific combination of immunostimulating compounds selected to increase the anti-tumor immune response to MAGE-A3. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Abbreviation: | | recombinant MAGE-A3 ASCI GSK1203486A | | | | Code name: | | GSK1203486A | | |
|
|
